Ovarian cancer is the deadliest of all the gynaecological cancers and survival rates lag behind vastly improved survival rates for other common cancers, such as breast and prostate cancer. Ovarian cancer is called the Silent Killer as most women are not diagnosed until it is at an advanced stage and difficult to treat, whereas if they were diagnosed at an early stage 90% of patients would survive.

Along with late diagnosis of the disease, one of the biggest challenges doctors face in treating ovarian cancer is that almost all sufferers will develop a resistance to chemotherapy over time. We are seeking funding for work which will address the urgent issue of chemotherapy resistance in ovarian cancer patients. Our research is highly innovative and will investigate preventing chemotherapy resistance by limiting the ability of ovarian cancer cells to change their shape.